The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $1.8 in the prior trading day, Kiora Pharmaceuticals Inc (NASDAQ: KPRX) closed at $1.88, up 4.44%. In other words, the price has increased by $4.44 from its previous closing price. On the day, 67028.0 shares were traded. KPRX stock price reached its highest trading level at $1.9 during the session, while it also had its lowest trading level at $1.79.
Ratios:
Our goal is to gain a better understanding of KPRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.79 and its Current Ratio is at 8.79. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPRX now has a Market Capitalization of 6914518 and an Enterprise Value of -12075558.
Stock Price History:
The Beta on a monthly basis for KPRX is -0.72, which has changed by -0.4478528 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, KPRX has reached a high of $4.18, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -23.18%, while the 200-Day Moving Average is calculated to be -34.23%.
Shares Statistics:
The stock has traded on average 44.62K shares per day over the past 3-months and 57880 shares per day over the last 10 days, according to various share statistics. A total of 3.43M shares are outstanding, with a floating share count of 3.33M. Insiders hold about 9.34% of the company’s shares, while institutions hold 16.75% stake in the company. Shares short for KPRX as of 1763078400 were 14110 with a Short Ratio of 0.32, compared to 1760486400 on 532. Therefore, it implies a Short% of Shares Outstanding of 14110 and a Short% of Float of 0.4.
Earnings Estimates
A comprehensive evaluation of Kiora Pharmaceuticals Inc (KPRX) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.45 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$2.03 and -$2.75 for the fiscal current year, implying an average EPS of -$2.39. EPS for the following year is -$2.23, with 1.0 analysts recommending between -$2.23 and -$2.23.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $1.5M. There is a high estimate of $1.5M for the next quarter, whereas the lowest estimate is $1.5M.
A total of 1 analysts have provided revenue estimates for KPRX’s current fiscal year. The highest revenue estimate was $1.5M, while the lowest revenue estimate was $1.5M, resulting in an average revenue estimate of $1.5M. In the same quarter a year ago, actual revenue was $16.02MBased on 1 analysts’ estimates, the company’s revenue will be $1.5M in the next fiscal year. The high estimate is $1.5M and the low estimate is $1.5M.
